New Neoplasms Findings from Regeneron Pharmaceuticals Inc. Described (Effect of Proprotein Convertase Subtilisin/kexin Type 9 Inhibition On Cancer Events: a Pooled, Post Hoc, Competing Risk Analysis of Alirocumab Clinical Trials).
In: Immunotherapy Weekly, 2023-09-05, S. 709-709
serialPeriodical
Zugriff:
Considering both treatment arms in aggregate, 969 (4.03%), 779 (3.24%), 178 (0.74%) and 167 (0.69%) patients developed any neoplasm, malignant neoplasms, broad definition of hormone-sensitive cancer and strict definition of hormone-sensitive cancer events, respectively. Keywords: Tarrytown; State:New York; United States; North and Central America; Alirocumab Therapy; Biopharmaceutical Companies; Business; Cancer; Clinical Research; Clinical Trials and Studies; Convertase; Drugs and Therapies; Endopeptidases; Enzymes and Coenzymes; Health and Medicine; Healthcare Biotechnology Companies; Hormones; Immunologic Agents; Immunotherapy; Lipid Research; Lipids; Lipoproteins; Monoclonal Antibodies; Neoplasms; Oncology; Peptide Hydrolases; Pharmaceuticals; Placebos; Proprotein Convertases; Risk and Prevention; Serine Endopeptidases; Serine Proteases; Subtilisins EN Tarrytown State:New York United States North and Central America Alirocumab Therapy Biopharmaceutical Companies Business Cancer Clinical Research Clinical Trials and Studies Convertase Drugs and Therapies Endopeptidases Enzymes and Coenzymes Health and Medicine Healthcare Biotechnology Companies Hormones Immunologic Agents Immunotherapy Lipid Research Lipids Lipoproteins Monoclonal Antibodies Neoplasms Oncology Peptide Hydrolases Pharmaceuticals Placebos Proprotein Convertases Risk and Prevention Serine Endopeptidases Serine Proteases Subtilisins 709 709 1 09/04/23 20230905 NES 230905 2023 SEP 5 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Research findings on Neoplasms are discussed in a new report. [Extracted from the article]
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
New Neoplasms Findings from Regeneron Pharmaceuticals Inc. Described (Effect of Proprotein Convertase Subtilisin/kexin Type 9 Inhibition On Cancer Events: a Pooled, Post Hoc, Competing Risk Analysis of Alirocumab Clinical Trials).
|
---|---|
Zeitschrift: | Immunotherapy Weekly, 2023-09-05, S. 709-709 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1090-8625 (print) |
Sonstiges: |
|